Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
TKMR's Cash to Debt is ranked higher than
97% of the 1256 Companies
in the Global Biotechnology industry.

( Industry Median: 47.96 vs. TKMR: No Debt )
TKMR' s 10-Year Cash to Debt Range
Min: 178.64   Max: No Debt
Current: No Debt

Equity to Asset 0.76
TKMR's Equity to Asset is ranked higher than
79% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. TKMR: 0.76 )
TKMR' s 10-Year Equity to Asset Range
Min: 0.03   Max: 0.9
Current: 0.76

0.03
0.9
Interest Coverage No Debt
TKMR's Interest Coverage is ranked higher than
70% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. TKMR: No Debt )
TKMR' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 11.39
M-Score: -99999999.99
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -136.87
TKMR's Operating margin (%) is ranked higher than
69% of the 1033 Companies
in the Global Biotechnology industry.

( Industry Median: -76.30 vs. TKMR: -136.87 )
TKMR' s 10-Year Operating margin (%) Range
Min: -22383.33   Max: 16.57
Current: -136.87

-22383.33
16.57
Net-margin (%) -197.02
TKMR's Net-margin (%) is ranked higher than
67% of the 1033 Companies
in the Global Biotechnology industry.

( Industry Median: -78.15 vs. TKMR: -197.02 )
TKMR' s 10-Year Net-margin (%) Range
Min: -19172.92   Max: 211.18
Current: -197.02

-19172.92
211.18
ROE (%) -45.14
TKMR's ROE (%) is ranked higher than
71% of the 1151 Companies
in the Global Biotechnology industry.

( Industry Median: -34.30 vs. TKMR: -45.14 )
TKMR' s 10-Year ROE (%) Range
Min: -984.09   Max: 129.35
Current: -45.14

-984.09
129.35
ROA (%) -34.93
TKMR's ROA (%) is ranked higher than
71% of the 1260 Companies
in the Global Biotechnology industry.

( Industry Median: -26.94 vs. TKMR: -34.93 )
TKMR' s 10-Year ROA (%) Range
Min: -58.63   Max: 146.65
Current: -34.93

-58.63
146.65
ROC (Joel Greenblatt) (%) -1653.38
TKMR's ROC (Joel Greenblatt) (%) is ranked higher than
65% of the 1234 Companies
in the Global Biotechnology industry.

( Industry Median: -394.00 vs. TKMR: -1653.38 )
TKMR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1691.29   Max: 249.49
Current: -1653.38

-1691.29
249.49
Revenue Growth (3Y)(%) -19.60
TKMR's Revenue Growth (3Y)(%) is ranked higher than
68% of the 699 Companies
in the Global Biotechnology industry.

( Industry Median: -1.10 vs. TKMR: -19.60 )
TKMR' s 10-Year Revenue Growth (3Y)(%) Range
Min: -29.8   Max: 268.4
Current: -19.6

-29.8
268.4
EBITDA Growth (3Y)(%) -10.60
TKMR's EBITDA Growth (3Y)(%) is ranked higher than
73% of the 699 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. TKMR: -10.60 )
TKMR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 40.6
Current: -10.6

0
40.6
EPS Growth (3Y)(%) -6.80
TKMR's EPS Growth (3Y)(%) is ranked higher than
76% of the 721 Companies
in the Global Biotechnology industry.

( Industry Median: -6.70 vs. TKMR: -6.80 )
TKMR' s 10-Year EPS Growth (3Y)(%) Range
Min: -50.4   Max: 30.8
Current: -6.8

-50.4
30.8
» TKMR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

TKMR Guru Trades in Q2 2013

Jean-Marie Eveillard Sold Out
» More
Q1 2014

TKMR Guru Trades in Q1 2014

Jim Simons 25,000 sh (New)
Steven Cohen 46,283 sh (New)
» More
Q2 2014

TKMR Guru Trades in Q2 2014

Jim Simons 150,200 sh (+500.8%)
» More
Q3 2014

TKMR Guru Trades in Q3 2014

Paul Tudor Jones 100,000 sh (New)
Jim Simons 22,900 sh (-84.75%)
» More
» Details

Insider Trades

Latest Guru Trades with TKMR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2013-06-30 Sold Out $4.28 - $5.05 $ 25.61440%0
Jean-Marie Eveillard 2013-03-31 New Buy$4.35 - $5.44 $ 25.61441%25000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 18.05
TKMR's Forward P/E is ranked higher than
96% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. TKMR: 18.05 )
N/A
P/B 6.97
TKMR's P/B is ranked higher than
72% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 6.38 vs. TKMR: 6.97 )
TKMR' s 10-Year P/B Range
Min: 0.32   Max: 262.5
Current: 6.97

0.32
262.5
P/S 32.57
TKMR's P/S is ranked higher than
74% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 28.95 vs. TKMR: 32.57 )
TKMR' s 10-Year P/S Range
Min: 0.74   Max: 32.98
Current: 32.57

0.74
32.98
EV-to-EBIT -21.91
TKMR's EV-to-EBIT is ranked higher than
55% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. TKMR: -21.91 )
TKMR' s 10-Year EV-to-EBIT Range
Min: -29.4   Max: 91.9
Current: -21.91

-29.4
91.9
Current Ratio 5.73
TKMR's Current Ratio is ranked higher than
77% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. TKMR: 5.73 )
TKMR' s 10-Year Current Ratio Range
Min: 0.98   Max: 7.2
Current: 5.73

0.98
7.2
Quick Ratio 5.73
TKMR's Quick Ratio is ranked higher than
78% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. TKMR: 5.73 )
TKMR' s 10-Year Quick Ratio Range
Min: 0.98   Max: 7.2
Current: 5.73

0.98
7.2
Days Sales Outstanding 42.71
TKMR's Days Sales Outstanding is ranked higher than
88% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 115.94 vs. TKMR: 42.71 )
TKMR' s 10-Year Days Sales Outstanding Range
Min: 2.76   Max: 996.15
Current: 42.71

2.76
996.15

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.20
TKMR's Price/Net Cash is ranked higher than
86% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 55.00 vs. TKMR: 7.20 )
TKMR' s 10-Year Price/Net Cash Range
Min: 0.71   Max: 38.5
Current: 7.2

0.71
38.5
Price/Net Current Asset Value 7.10
TKMR's Price/Net Current Asset Value is ranked higher than
84% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 31.07 vs. TKMR: 7.10 )
TKMR' s 10-Year Price/Net Current Asset Value Range
Min: 0.7   Max: 209
Current: 7.1

0.7
209
Price/Tangible Book 6.00
TKMR's Price/Tangible Book is ranked higher than
78% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 9.50 vs. TKMR: 6.00 )
TKMR' s 10-Year Price/Tangible Book Range
Min: 0.64   Max: 177.5
Current: 6

0.64
177.5
Price/DCF (Projected) 8.80
TKMR's Price/DCF (Projected) is ranked higher than
92% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. TKMR: 8.80 )
TKMR' s 10-Year Price/DCF (Projected) Range
Min: 3.92   Max: 27.65
Current: 8.8

3.92
27.65
Price/Median PS Value 8.10
TKMR's Price/Median PS Value is ranked higher than
68% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 2.32 vs. TKMR: 8.10 )
TKMR' s 10-Year Price/Median PS Value Range
Min: 0.28   Max: 6.65
Current: 8.1

0.28
6.65
Earnings Yield (Greenblatt) -4.60
TKMR's Earnings Yield (Greenblatt) is ranked higher than
76% of the 1236 Companies
in the Global Biotechnology industry.

( Industry Median: -5.70 vs. TKMR: -4.60 )
TKMR' s 10-Year Earnings Yield (Greenblatt) Range
Min: -4.6   Max: 99478.9
Current: -4.6

-4.6
99478.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:TKM.Canada, I9DN.Germany,
Tekmira Pharmaceuticals Corp was incorporated on October 6, 2005. The Company develops ribonucleic acid interference therapeutic product candidates as well as provides its lipid nanoparticle delivery technology to pharmaceutical partners in the Canada. The Company's internal product development candidates include TKM-PLK1, an oncology product candidate that is in Phase I clinical trials to kill cancer cells; and TKM-Ebola, an antiviral product, which is in Phase I of clinical trials for the treatment of the Zaire species of Ebola virus infection. In addition, the Company has licenses from Alnylam targeting two validated oncology targets, WEE1 and CSN5; and to develop TKM-ALDH2, a systemically delivered RNAi therapeutic that utilizes lipid nanoparticle technology for the treatment of alcohol dependence.
» More Articles for TKMR

Headlines

Articles On GuruFocus.com
Tekmira Pharmaceuticals Gets Mixed Ratings After Ebola Drug Updates Nov 11 2014 
Ebola: Is The Cure Out There? Oct 14 2014 
Ebola Diagnosis in U.S. Raises Pharmaceutical Stock by 20% Oct 01 2014 

More From Other Websites
Nasdaq stocks posting largest percentage increases Jan 29 2015
Tekmira Pharmaceuticals, Lakeland Industries Moving On Possible Ebola Case In California Jan 29 2015
TEKMIRA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 28 2015
TEKMIRA PHARMACEUTICALS CORP Files SEC form 8-K/A, Entry into a Material Definitive Agreement,... Jan 26 2015
Tekmira Pharmaceuticals Corporation (TKMR): Falcon Edge Capital Discloses 10% Passive Stake Jan 26 2015
5 stocks to watch Jan 22 2015
Tekmira Initiates Phase I Clinical Trial of TKM-HBV Jan 21 2015
TEKMIRA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 21 2015
Tekmira Initiates Phase I Clinical Trial of TKM-HBV Jan 21 2015
Vical Up on Deal with AnGes to Develop Ebola Treatment - Analyst Blog Jan 15 2015
Wall Street's Wheelings And Dealings Jan 13 2015
Chimerix tackles Ebola outbreak Jan 13 2015
TEKMIRA PHARMACEUTICALS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Jan 12 2015
Will The Rally In Tekmira Pharmaceuticals Hold? Jan 12 2015
Tekmira Purchases OnCore Biopharma To Find Hep B Cure Jan 12 2015
Is the Merger a Great Deal for Tekmira Shareholders? Jan 12 2015
Tekmira teams up with OnCore to focus on hepatitis B cure Jan 12 2015
Tekmira teams up with OnCore to focus on hepatitis B cure Jan 12 2015
Tekmira Pharmaceuticals (TKMR) Stock Soars After OnCore Biopharma Acquisition Announcement Jan 12 2015
Morning Movers: Tiffany Tumbles as Sales Disappoint; Lululemon Jumps Jan 12 2015
Tekmira Pharmaceuticals Soars 50% Following OnCore Biopharma Merger Jan 12 2015
Canada's Tekmira to buy US-based OnCore Biopharma, focus on HBV treatment Jan 11 2015
Tekmira Pharmaceuticals and OnCore Biopharma Announce Merger Agreement to Create Leading Global... Jan 11 2015
Tekmira Pharmaceuticals and OnCore Biopharma Announce Merger Agreement to Create Leading Global... Jan 11 2015
From Ebola To Police Protests Retail Investors Bought The News In 2014 Jan 05 2015
Tekmira Pharmaceuticals (TKMR) Stock Surges Today After Clinical Study Update Dec 31 2014
Tekmira Establishes Manufacturing and Clinical Trial Agreement to Provide TKM-Ebola-Guinea for... Dec 22 2014
Tekmira Receives Clearance to Conduct a Phase I Clinical Study With TKM-HBV Dec 22 2014
Tekmira Pharmaceuticals Announces Leadership Changes Dec 19 2014
Tekmira Files Shelf Registration Statement Nov 26 2014
Tekmira Provides Key Highlights of Analyst and Investor Day in New York Nov 21 2014
Tekmira Announces Licensing and Collaboration Agreement With Dicerna Nov 17 2014
Tekmira to Present at Stifel Healthcare Conference Nov 12 2014
Tekmira tops 3Q revenue forecasts Nov 07 2014
Tekmira Provides Corporate Update and Announces Third Quarter 2014 Results Nov 06 2014
Tekmira to Host Analyst Day on November 21 in New York City Nov 05 2014
Tekmira Conference Call and Webcast Advisory: Corporate Update and Third Quarter Financial Results Oct 23 2014
Tekmira Provides Periodic Update on TKM-Ebola Program Oct 21 2014
Tekmira Presents Results of Preclinical Studies With Hepatitis B Therapeutic Oct 15 2014
US STOCKS-Salix jumps after terminated merger deal, upgrade Oct 03 2014
US STOCKS-RadioShack, Tekmira among biggest premarket movers Oct 03 2014
US stocks sink on economic, Ebola worries Oct 01 2014
US stocks fall on mixed economic data Oct 01 2014
Ahead of the Bell: Ebola treatment makers rise Oct 01 2014
Shares of companies testing Ebola vaccines rise Sep 30 2014
US stocks mixed as European equities tumble Sep 23 2014
Gene studies of Ebola in Sierra Leone show virus is mutating fast Aug 28 2014
Evidence suggests Ebola toll vastly underestimated -WHO Aug 14 2014
NewLink Genetics: Ready to test Ebola vaccine Aug 14 2014
Guinea declares public health emergency over Ebola Aug 14 2014
Guinea declares public health emergency over Ebola Aug 14 2014
Drugmaker not ready to use Ebola drug in Africa Aug 13 2014
WHO hopes for more Ebola drug doses, vaccine progress by end of year Aug 12 2014
Ebola: Questions, answers about an unproven drug Aug 12 2014
US stocks finish higher amid global equity rally Aug 11 2014
US stocks extend rise in global equity rally Aug 11 2014
US STOCKS-Wall St rebounds, erases week's losses with Russia news Aug 08 2014
Ebola drugmaker's shares surge after US eases restrictions Aug 08 2014
US stocks surge as US strikes jihadists in Iraq Aug 08 2014
US STOCKS-Wall St rebounds, erases week's losses with Russia news Aug 08 2014
US STOCKS-Wall St rebounds on news Russia ending drills Aug 08 2014
US STOCKS-Wall St rises despite Iraq air strikes; indexes off for week Aug 08 2014
US STOCKS-Utilities boost Wall Street as bombs fly in Iraq Aug 08 2014
Ebola drug company Tekmira's shares jump as US allows use on infected humans Aug 08 2014
FDA lifts hold on experimental Ebola drug Aug 07 2014
Tekmira Announces Completion of Underwritten Public Offering of Common Stock Mar 18 2014
Tekmira Announces Pricing of Underwritten Public Offering of Common Stock Mar 13 2014
Tekmira Announces Proposed Public Offering of Common Stock Mar 10 2014
Tekmira Provides Corporate Update and Announces Year-End 2013 Results Mar 06 2014
Tekmira Receives Fast Track Designation From FDA for Its Anti-Ebola Viral Therapeutic Mar 05 2014
Tekmira Conference Call and Webcast Advisory: Corporate Update and 2013 Year-End Financial Results Mar 04 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK